RANIライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:43):

Stats
本日の出来高	17 691.00
平均出来高	130 953
時価総額	331.73M
EPS	$0 ( 2024-03-27 )
次の収益日	( $-0.200 ) 2024-05-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.95
ATR14	$0.0330 (0.50%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-21	Mckinley Kate	Buy	323 500	Stock Option (Right to Buy)
2024-03-21	Hashim Mir	Buy	323 500	Stock Option (Right to Buy)
2024-03-21	Groen Eric	Buy	323 500	Stock Option (Right to Buy)
2024-03-21	Imran Talat	Buy	1 085 000	Stock Option (Right to Buy)
2024-03-21	Sanford Svai S	Buy	323 500	Stock Option (Right to Buy)

INSIDER POWER
19.25
Last 99 transactions
Buy: 12 150 348 \| Sell: 8 157 844

ボリューム相関

長: -0.25 (neutral)

短: 0.53 (weak)

Signal:(48.248) Neutral

Rani Therapeutics 相関

10 最も正の相関
LWAY	0.823

10 最も負の相関
FAT	-0.836
APPF	-0.832
FSTR	-0.826
DATS	-0.825
ENTG	-0.825
ALGT	-0.818

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Rani Therapeutics 相関 - 通貨/商品

0.53
( weak )

0.63
( weak )

0.00
( neutral )

0.58
( weak )

0.87
( strong )

-0.59
( weak negative )

Rani Therapeutics 財務諸表

Annual	2023
収益:	$0
総利益:	$-822 000 (0.00 %)
EPS:	$-1.330

FY	2023
収益:	$0
総利益:	$-822 000 (0.00 %)
EPS:	$-1.330

FY	2022
収益:	$0
総利益:	$-1.31M (0.00 %)
EPS:	$-2.66

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.445

Financial Reports:

No articles found.

Rani Therapeutics

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.